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The purpose of this guideline is to direct urologists and patients regarding how to identify overactive
bladder (OAB) in male patients with lower urinary tract symptoms (LUTS) and to make an accurate
diagnosis and establish treatment goals to improve the patients' quality of life (QoL). LUTS are commonly
divided into storage, voiding, and postmicturition symptoms, and are highly prevalent in elderly men.
LUTS can result from a complex interplay of pathophysiologic features that can include bladder
dysfunction and bladder outlet dysfunction such as benign prostatic obstruction (BPO) or poor relaxation
of the urethral sphincter. Diagnosis of OAB in male LUTS leads to accurate diagnosis of pure OAB and
bladder outlet-related OAB, and appropriate treatment in men with residual storage symptoms after
treatment for LUTS.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Purpose
The purpose of this guideline is to direct urologists and patients
regarding how to identify overactive bladder (OAB) from male pa-
tients with lower urinary tract symptoms (LUTS) and to make an
accurate diagnosis and establish treatment goals to improve pa-
tients' quality of life (QoL).
2. Male LUTS and OAB e background
2.1. LUTS are highly prevalent among older men and have a
negative impact on health-related QoL (HRQoL). (LE 1a, Grade A)
OAB is associated with medical diseases such as diabetes and
congestive heart failure. (LE 2b, Grade B) OAB and urinary
incontinence symptom severity progress dynamically and are
also sustained over time. (LE 2a, Grade B)
OAB is a clinical diagnosis deﬁned by the International Conti-
nence Society as the presence of “urinary urgency, usually accom-
panied by frequency and nocturia, with or without urgency urinaryddhist Tzu Chi General Hos-
an.
ciation. Published by Elsevier Taiwincontinence, in the absence of a urinary tract infection or other
obvious pathology”.1 OAB symptoms can be bothersome and can
negatively affect HRQoL, increase anxiety and depression, and in-
crease health care usage. The strongest predictor of OAB-associated
bother was urinary urgency.2 OAB also adversely affects sexuality in
both men and women.3 OAB is common in older adults and is
associated with substantial impairment in mental health and
HRQoL, but rates of treatment seeking behavior are low.4
Urgency is the core symptom for the presence of OAB. It has
been estimated that 10e16% of the population in the world has the
OAB condition.5 However, although an urgency severity scale has
been suggested, the grade of urgency is reported subjectively by the
patients; therefore, there could be awide variation among different
grades of the reported urgency severity.6
The incidence of LUTS, including OAB in men, increases with
age. Frequent comorbidity with potential prostatic disease adds
complexity to the management of male LUTS.7 In addition, patients
with congestive heart failure had more storage urinary symptoms
suggestive of OAB than did the age-matched controls.8 Patients
with type 2 diabetes mellitus present more OAB symptoms such as
urgency and nocturia than controls. Among diabetic patients, a
higher glycosylated hemoglobin level represents an independent
predictor of OAB/urgency, urge urinary incontinence and nocturia.9
OAB and urinary incontinence symptom severity progress
dynamically and are also sustained over time. Although symptoman LLC. Open access under CC BY-NC-ND license.
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also persist over long time periods.102.2. OAB is also prevalent in men and frequently associated with
LUTS in men. Men with bladder outlet obstruction (BOO) may
have OAB symptoms, but OAB may exist independently of BOO in
elderly men. (LE 2a, Grade B) Antimuscarinics, in combination
with alpha1-receptor antagonists, or alone, improve OAB
symptoms in men with and without BOO. (LE 1a, Grade A)
The prevalence of moderate/severe urinary incontinence was
4.5% in men. Prevalence increased with age from 0.7% at 20e34
years old, to 16.0% at  75 years old (p < 0.001).11 It has been
estimated that 29.8 million adults aged  40 years in the United
States have bothersome OAB symptoms. The prevalence of OAB
symptoms at least “sometimes” was 27.2% in men.12 In a longitu-
dinal population-based survey, urinary incontinence and other
LUTS constitute dynamic conditions. There was a marked overall
increase in the prevalence of urinary incontinence, OAB, and noc-
turia in the same individual from 1991 to 2007.13
Recent concepts on male incontinence have shifted from benign
prostatic obstruction (BPO), BOO, or post-radical prostatic surgery
to the bladder conditions. Other important pathological conditions
such as nocturnal enuresis and postmicturition dribbling are also
clinically relevant.14 Among the LUTS, storage LUTS was more
prevalent than voiding or postmicturition LUTS in men (44.6%,
28.5%, 15.9%, respectively). The most prevalent LUTS was nocturia
(36.6%) in men.15 Men with bothersome OAB were signiﬁcantly
more likely to seek treatment and report the lowest levels of
HRQoL.16
The overall incidence of detrusor overactivity (DO) was 76.1% in
male OAB patients, 63% of men with urgency (OAB dry) had DO,
while 93% of men with urgency and urgency urinary incontinence
(OAB wet) had DO. There was a better correlation in results be-
tween OAB symptoms and the urodynamic diagnosis of DO in men
than in women, more so in OAB wet than in OAB dry.17
Pharmacotherapies that target the prostate often fail to alle-
viate OAB symptoms, and may not be the most appropriate ther-
apy for men with storage LUTS. Multiple studies have suggested
that antimuscarinics alone or in combination with alpha1-receptor
antagonists improve OAB symptoms in men with and without
BOO. Therefore, in the diagnosis and treatment of male LUTS
associated with OAB, greater understanding of the pathophysi-
ology of OAB that underlies male LUTS, and examination of the
relationship between symptoms and urodynamic ﬁndings are
needed.183. Clinical symptoms e urgency is core symptom
3.1. Diagnosis of OAB in male patients with LUTS should be based
on symptom of urgency with/without urgency incontinence.
(Grade A) The grade of urgency should be carefully evaluated and
BOO, neurogenic lesions, and cognitive function should be
carefully assessed prior to making a ﬁnal diagnosis of idiopathic
OAB. (Grade A)
Men with LUTS commonly experience coexisting storage, void-
ing, and postmicturition symptoms.15 LUTS, OAB, urinary inconti-
nence, and LUTS/BOO are highly prevalent conditions, emphasizing
the need for comprehensive urological assessments of LUTS in
men.19,20 The prevalence of incontinence ranges from 11% to 34%
among community-dwellingmen aged 65 years. Benign prostatic
hyperplasia (BPH)-related incontinence may be related to pro-
gression of BPH or as a postsurgical complication.21Urgency should be the primary or co-primary endpoint for
future studies of OAB and detrusor overactivity. Greater clarity is
needed in the development of instruments for measuring urgency,
so that they do not confuse urgency with normal bladder sensa-
tions; more education and guidance are needed on how urgency is
deﬁned.22 Urgency sensation scales or urgency severity scales (USS)
have been developed to assess the urinary urgency in men with
LUTS-associated OAB.23 A high urgency severity score (USS) recor-
ded in conjunctionwith a voiding diary and OAB wet were strongly
associated with urodynamic DO.24
BPH patients with DO may neglect the symptom of urgency due
to abnormal bladder sensation, or negate the symptom by sub-
conscious sphincter contraction to abort the overactivity. Among
the 84 BPH-DO patients, 52 reported the symptom of urgencywhile
32 did not.25
First sensation ratio and bladder urgency velocity statistically
signiﬁcantly correlated with the Urgency Perception Score Uro-
dynamic variables correlated with bladder sensation question-
naire scores and may be an objective method to assess sensory
dysfunction.26 Reduced bladder sensation is deﬁned as bladder
volume at the ﬁrst sensation > 300 mL. Increased bladder
sensation is deﬁned as bladder volume at the ﬁrst sensation <
100 mL.27
4. Diagnostic tests and differential diagnosis of idiopathic
OAB from BOO associated OAB and other bladder conditions
4.1. The initial assessment of OAB in men with LUTS should
include the past history, present illness, physical examination,
and laboratory examination. (Grade A) In men with BPH and OAB
symptoms, the OAB is usually secondary to BOO. In men, BOO is
not likely, and the OAB symptoms might be idiopathic. (Grade D)
Patients presented with urgency frequency symptoms which
could be due to psychological factors, increased urine production,
uninhibited urge due to central nervous lesions, or having DO. Ur-
gency symptom can be caused by sensory dysfunction (hypersen-
sitive bladder) or DO. Sensory urgency might be due to micro-
motion of the detrusor during bladder ﬁlling (increased excit-
ability), rapid bladder ﬁlling or diuresis, urothelial dysfunction, or a
high sensory perception due to anxiety, depression, or emotional
stress. A differential diagnosis of OAB should exclude other pa-
thologies such as psychological distress, interstitial cystitis, UTI,
bladder tumor, and urolithiasis.
4.1.1. Past history
A family history of prostatic disease and prostatic cancer, pre-
vious history of lower urinary tract diseases such as bladder stone,
cystoscopic examination, transurethral surgery, any systemic dis-
ease (diabetes, hypertension, cerebral vascular accident, Parkin-
son's disease (PD), chronic obstructive pulmonary disease, asthma,
etc.), and medical history (alpha-blocker, 5-alpha-reductase in-
hibitor, antimuscarinics, neurological medication) should be
recorded.
4.1.2. Present illness
The duration of LUTS (acute or chronic onset) and associated
symptoms should be recorded. The LUTS can be assessed using the
International Prostate Symptom Score (IPSS) or the American
Urological Association Symptom Index (AUA-SI).28 The total
symptom score can be classiﬁed as mild (< 8), moderate (8e19),
and severe (> 20).29 The dominant symptoms should be assessed
according to the storage and empty symptoms, separately. Daily
ﬂuid intake is important. Excessive ﬂuid intake can produce voiding
patterns that mimic OAB symptoms. A ﬂuid diary can be helpful in
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quency consists of voiding every 3e4 hours, with a median of
approximately six voids/day.30 Comorbid conditions such as
neurologic diseases and other genitourinary conditions should be
considered as they directly impact bladder function. In addition,
polydipsia and polyuria-related frequency might be considered in
differential diagnosis; a frequency volume chart is helpful.
4.1.3. Physical examination
Patients should be examined systemically and locally. The
presence of an abdominal scar, a palpable distended bladder, and
genital lesion should be carefully examined. Digital rectal exami-
nation (DRE) for the prostatic consistency, prostatic size, surface,
and any abnormal nodularity should be carefully examined. In
addition, a focal neurological examination such as bulbocavernosus
reﬂex, anal sphincter contraction, and saddle sensation should be
examined during DRE.
4.1.4. Laboratory tests
When a patient complains of urethral symptoms (micturition
pain, burning sensation), a urinalysis should be performed. When
the urinalysis shows microscopic hematuria or pyuria, a kidney
ureter bladder (KUB) X-ray should be ordered to investigate the
presence of a bladder or lower ureteral stone. Blood urea-nitrogen
and creatinine levels should be investigated when chronic urinary
retention is noted. Prostatic speciﬁc antigen (PSA) level is indicated
in all patients with an enlarged prostate or abnormal DRE ﬁnding,
except in the elderly (e.g., > 80 years old).
4.1.5. Urodynamic study
Uroﬂowmetry (including maximum ﬂow rate, voided volume,
and ﬂow pattern) and subsequent postvoid residual (PVR) should
be measured concomitantly. Bladder sonography is indicated to
measure the PVR and to investigate bladder stone, bladder wall
thickness,31 and intravesical prostatic protrusion.32 Increased
bladder wall thickness and intravesical prostatic protrusion have
been demonstrated to be associated with BOO and OAB symptoms.
Mean bladder wall thickness is associated with a symptom history
of OAB and mixed urinary incontinence (MUI), higher daytime and
night time frequency, and higher visual analog scale (VAS) scores.31
Although a uroﬂow study has been found to have poor diag-
nostic speciﬁcity for BOO,29 uroﬂowmetry should be performed in
menwith LUTS and OAB. A cystometry or pressure ﬂow study is not
recommended as the ﬁrst line investigation for OAB diagnosis un-
less the initial treatment fails based on the clinical symptoms and
uroﬂowmetry.
4.1.6. OAB questionnaires
OAB, especially in patients with urgency incontinence, eventu-
ally has a negative impact on HRQoL. Urinary frequency can be
reliably measured with a voiding diary. Traditionally, up to seven
micturition episodes during waking hours has been considered
normal.33 However, becausemultiple factorsmight cause confusion
of OAB, multi-item questionnaires have been introduced to eval-
uate the impact of OAB and of treatment outcomes, such as OAB
symptom score (OABSS) and OAB-q.16,34,35 By contrast, there is no
disease-speciﬁc HRQoL instrument that serves as a “gold standard”
for OAB patients.36
Kelleher et al37 published the King's Health Questionnaire
(KHQ) which covered dimensions of importance to OAB patients,
particularly urgency and frequency. The KHQ was developed with
patient input and has been validated in a large cohort of incontinent
women. The bladder problem question of the KHQ shows the
greatest promise as single-item scales to assess problem intensity
in OAB patients.38 This questionnaire is also validated in Chineseand was demonstrated to be a reliable instrument for the assess-
ment of HRQoL in patients with OAB.39
Measuring IPSS subscores and calculating IPSS-V/S is a simple
and useful method to differentiate failure to voiding and failure to
storage LUTD in men with LUTS. IPSS-V/S may provide a guide for
the initial treatment, especially for primary care physicians without
access to urological studies.40 Initial treatment with doxazosin for
patients with IPSS-V/S > 1 and tolterodine for patients with IPSS-V/
S  1 is safe and feasible.41 Combination of IPSS-T with total
prostate volume (TPV) and Qmax increases the PPV of bladder
outlet-related LUTD. Furthermore, including IPSS-V/S > 1 or > 2
into the equation results in a higher PPV than IPSS-T. IPSS-V/S > 1 is
a stronger predictor of bladder outlet-related LUTD than IPSS-T.42
5. Differential diagnosis between idiopathic OAB and
neurogenic OAB
5.1. Although this guideline does not deal with neurogenic
voiding dysfunction, elderly men with LUTS and OAB might also
have latent neurological lesions that may not be discovered at the
initial examination. (LE 2a, Grade B) A detailed history taking and
neurological examination including bulbocavernosus reﬂex, deep
tendon reﬂex test, and saddle anesthesia will be helpful in
differentiation between idiopathic and neurogenic OAB. (Grade A)
LUTS are highly prevalent in stroke patients and have a major
impact on daily life. Themost frequent symptomwas nocturia (76%)
followed by urgency (70%), and daytime frequency (59%). The most
severe symptom was urgency followed by nocturia, and daytime
frequency.43 Double incontinence (urinary and fecal incontinence)
was more prevalent than isolated incontinence in patients after
stroke during post-acute rehabilitation.44
In patients with stroke and voiding dysfunctions, a careful
urodynamic study should be performed to identify the presence of
BOO or dysfunctional voiding. Voiding dysfunction is also a sig-
niﬁcant problem in patients with a head injury. Bladder hyper-
reﬂexia is seen in patients with injuries above the pontine
micturition center. The voiding abnormality has a good prognosis
and resolves spontaneously.45
Themost prevailing urinary symptom in idiopathic PD (IPD) was
nocturia (77.5%) followed by urgency (36.7%), and frequency
(32.6%). Urodynamic tests revealed neurogenic DO in 33 patients
(67.3%), detrusor underactivity in six patients (12.2%), and 10
(20.4%) patients with normal detrusor function. The irritative uri-
nary symptoms manifested urodynamically as neurogenic detrusor
overactivity are more common in IPD patients than obstructive
symptoms.46
One study investigated the LUTS and urodynamic and cysto-
metric ﬁndings in PD, dementia with Lewy bodies, and Alzheimer's
disease (AD). Urgency and urge incontinence are more prevalent in
dementia with Lewy bodies than in PD and AD, whereas mean
voided volume, free ﬂow, cystometric bladder capacity, and
detrusor pressure were similar in the groups; DO in 92% of the
patients with dementia with Lewy bodies, 46% of the patients with
PD, and 40% of the patients with AD.47
In the dedicated diabetic center in which all patients were
screened, 22.5% had OAB, and 48.0% of those with OAB had in-
continence.48 After multivariate analysis, age and male sex, and age
and waist circumferencewere independent risk factors for OAB and
OAB wet, respectively, however, glycated hemoglobin and C-reac-
tive protein levels were not. This ﬁnding suggests that the severity
of diabetes mellitus (DM) contributes little to OAB. Men with DM
and LUTS can present with varied urodynamic ﬁndings, apart from
the classic sensory or motor cystopathy. Urodynamic studies
showed impaired ﬁrst sensation (> 250 mL), increased capacity
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(more than one third of capacity), and BOO (Abrams-Grifﬁths
number > 40) in 23.1%, 25.0%, 78.8%, 38.5%, 65.4%, and 28.8% of the
men, respectively.49
Men with DM and LUTS can present with DO, detrusor under-
activity, and BOO. Noninvasive tests did not allow the identiﬁcation
of these. Only urodynamic evaluation is able to determine symp-
tom etiology. There is a relatively low prevalence of BOO in diabetic
patients with prostate enlargement and LUTS. Of the 50 patients in
the study, 23 (46%) had BOO. There was no correlation between the
IPSS, uroﬂowmetry, PVR urine or prostate volume, and the presence
of BOO (p > 0.05). Noninvasive tests did not allow the identiﬁcation
of these. Only urodynamic evaluation is able to determine symp-
tom etiology.50
6. Urodynamic study for OAB in male LUTS
6.1. Male LUTS may originate from bladder dysfunction or
bladder outlet disorders. (LE 2b, Grade B) DO and urethral
sphincter dysfunction should also be considered in young men
with LUTS or small prostate. (LE 2b, Grade B)
LUTS in men is highly prevalent and storage LUTS is more
prevalent than voiding or postmicturition symptoms.7,11,51
Although OAB wet is usually associated with urodynamic DO, the
OAB symptoms might involve other bladder dysfunction or outlet
disorders. Initial treatment based on predominant symptoms
without urodynamic testing is encouraging, but a urodynamic test
is recommended when the initial management fails to resolve the
storage LUTS.
A urodynamic study is useful in the evaluation of young men
presenting with LUTS; abnormal urodynamic ﬁndings were noted
in 36 (72%) patients, including DO in nine (18%) patients, detrusor
underactivity/acontractility in ﬁve (10%) patients, and BOO in 21
(42%) patients. Fourteen (28%) individuals had primary bladder
neck dysfunction and ﬁve (10%) individuals had BPH.52 About one
third of men with LUTS who were > 55 years of age had BPO.
Patients < 55 years old were more likely to have poor relaxation of
the urethral sphincter as a likely cause of LUTS.53 In a group of men
with LUTS and small prostate, BOO was the main ﬁnding, affecting
50.0% of the patients, followed by detrusor underactivity (DU) in 41
(48.8%) patients and DO in 28 (33.3%) patients.54
6.2. Urodynamic testing is indicated especially when male
patients with LUTS are ready to undergo invasive therapy for
LUTS, such as transurethral resection of the prostate (TURP) or
laser prostatectomy. (LE 2b, Grade B) More clinically objective
parameters should be investigated to provide a high correlation
with urodynamic results such as BOO or DO, to achieve a higher
success rate of treatment outcome of LUTS in men. (Grade D)
Because the correlation between LUTS, DRE, cystoscopy with
BOO is poor,55 a urodynamic study has been regarded as the only
way of establishing the diagnosis of BOO.56 Although a urodynamic
study is not necessary in the short term treatment of LUTS/BPH,
most urologists believe that a pressure ﬂow study should be un-
dertaken before surgery in neurologically normal men with LUTS
and a low Qmax,57 and men with LUTS and voiding dysfunction of
uncertain etiology.
There were weak correlations between OAB symptoms and
urodynamic ﬁndings. Most men with OAB symptoms had
concomitant voiding symptoms and more than one third (43%) of
these had evidence of BOO.58 A pressure ﬂow study provides
valuable information on detrusor function, however, a urody-
namic study also has some morbidity, such as urinary tractinfection in 4e6%, and dysuria in 75% of men with BOO and 55% of
men without BOO.59 Although a pressure ﬂow study can establish
the diagnosis of BOO, the symptomatic outcome of treatment
modalities for BPH did not differ among different degrees of
BOO.60
A videourodynamic study provides a more accurate diagnosis of
BPO and other bladder and urethral conditions responsible for
LUTS, such as DO, impaired detrusor contractility, hypersensitive
bladder, poor relaxation of urethral sphincter, bladder neck
dysfunction, pseudodyssynergia, detrusor underactivity, and
normal bladder and urethra.61 In patients with both storage and
empty LUTS, the incidence of DO increases with age, while the
incidence of poor relaxation of urethral sphincter increases as age
decreases.53
In patients with clinical BPH, DO is independently associated
with age and BOO. Among 1418 men investigated (median age: 63
years), 864 (60.9%) had DO. In a univariate analysis, men with DO
were signiﬁcantly older, more obstructed, had larger prostates,
higher irritative IPSS subscores, a lower voiding volume at free
uroﬂowmetry, and a lower bladder capacity at cystometry.62
OAB is a symptom syndrome which includes either sensory
dysfunction or a combination of sensory andmotor disorders of the
urinary bladder. In a group of men and women with persistent
storage symptoms, 89% of patients whose primary symptoms were
frequency and urgency had urodynamic DO.63 Not all patients with
OAB can have uninhibited detrusor contractions occurring during
bladder ﬁlling. A urodynamic study can only detect about 50% of
patients with OAB symptoms.64 BOOmay cause DO, however, many
studies have reported only 45e50% of men with LUTS have uro-
dynamically conﬁrmed DO and BOO.65,66
The ageing process results in intrinsic urethral sphincteric
deﬁciency which increases the prevalence of urinary incontinence
and may potentiate DO and OAB symptoms. Under this consider-
ation, a urodynamic study has been considered as useless in the
diagnosis of OAB. However, a urodynamic study is essential in
differential diagnosis of etiologies of OAB such as BOO, DO with
impaired detrusor contractility, dysfunctional voiding, and mixed
urinary incontinence.67
OAB symptoms of urge incontinence are found to be strongly
correlated with DO in men. Hyman et al68 found that a higher
incidence of DO was associated with urge incontinence than with
other LUTS in men. Of the men with LUTS, 68% had BOO, including
46% of men with DO. Hashim and Abrams69 found that the corre-
lation between OAB symptoms and urodynamic DO was better in
men than in women. Sixty-nine percent of men and 44% of women
with urgency (OAB dry) had DO, while 90% of men and 58% of
womenwith urgency and urgency incontinence (OAB wet) had DO.
They concluded that the bladder is a better and more reliable
witness in men than in women. The incidence of urodynamic DO
was more commonly seen in patients with BOO such as BPH,
bladder neck dysfunction, and DSD, but not in those with bladder
sensory disorder and an underactive bladder. A urodynamic study
is necessary if clinical presentations favor pathological causes other
than hypersensitive bladder.53
In the clinical practice, treatment of OAB is based on the sub-
jective symptoms of urgency and frequency; treatment with anti-
muscarinics in patients without DO might fail. A signiﬁcant
increase in bladder capacity during the cystometric study was
shown only in patients with DO, whereas no statistically signiﬁcant
improvement was shown in patients without DO. Treatment with
solifenacin was shown to be effective only in patients with invol-
untary detrusor contractions at the cystometric study.70 However,
one study revealed that urodynamics status could not predict
treatment outcomes between patients treated with tolterodine-
extended released (ER) or placebo, suggesting that anticholinergic
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the need for urodynamics studies.71
A recent study assessed the effects of onabotulinumtoxinA
(Botox) on clinical and urodynamic variables in patients with
idiopathic OAB. Improvements in urodynamic parameters and
clinical outcomes generally trended together following onabotu-
linumtoxinA treatment, with or without baseline DO. Therefore,
successful idiopathic OAB treatment with onabotulinumtoxinA
does not appear to be related to the pretreatment ﬁnding of
DO.72
7. Conservative treatment e behavioral modiﬁcation,
percutaneous tibial nerve stimulation, and sacral nerve
stimulation
7.1. Patients should be educated about drinking habits and
lifestyle modiﬁcation as the ﬁrst line treatment of OAB before
medication is started. (LE 2b, Grade B) Most OAB treatments
improve patient symptoms but are unlikely to eliminate all
symptoms. (LE 1b, Grade B) Patients should be encouraged to
continue behavioral modiﬁcation even though they are
successfully treated with medication. (LE 2b, Grade B)
Initial management of OAB-associated male LUTS included basic
diagnostic tests to exclude an underlying disease or condition such
as UTI. Treatment is mostly conservative (lifestyle interventions,
physiotherapy, physical therapy, pharmacotherapy) and is of an
empirical nature.73
Behavioral therapy and pelvic ﬂoor muscle training have been
tried to relieve this bothersome syndrome. Behavioral therapy for
OAB includes regular water intake (1.5e2 L daily), time voiding,
inhibiting urge sensation, and avoiding irritants or diuretics. These
behavioral modiﬁcations should be conducted after excluding BOO,
contracted bladder, or other bladder pathologies.74 The aim of
bladder re-education is to teach the central nervous system (CNS)
memory to accommodate bladder sensation and elevate the sen-
sory threshold of voiding desire.
Most OAB patients do not experience complete symptom relief;
most patients experience signiﬁcant reductions in symptoms and
improvements in QoL. Behavioral therapy with bladder drill pro-
vides effective therapy results for OAB.75,76 Weight loss also has
positive effects on older women with incontinence.77 Fluid man-
agement with a 25% reduction in ﬂuid intake reduced frequency
and urgency.78 A bladder training study reducing caffeine intake
also resulted in reductions in voiding frequency.79 Behavioral
treatments are generally either equivalent to or superior to medi-
cations in terms of reducing incontinence episodes, improving
frequency, and improving QoL.80e82
8. Medical treatment e for BOO, alpha-blocker,
antimuscarinics, and combined therapy
8.1. Antimuscarinics or beta-3 adrenoceptor agonists are
recommended for men with LUTS suggestive of OAB and without
evidence of BOO. (LE 1a, Grade A) Men with both voiding and
storage LUTS are recommended to take alpha-blockers with/
without 5-alpha-reductase inhibitors (5ARI) ﬁrst, followed by
antimuscarinics (LE 2a, Grade B) or beta-3 adrenoceptor agonists.
(Grade D)
Traditional medication for OAB is antimuscarinic agents tar-
geting the muscarinic receptors. Through blockage of receptors, the
contractility of the detrusor smooth muscle decreases and the
symptoms of OAB can be relieved. The role of muscarinic M2 re-
ceptors is found to inhibit the relaxation effect of norepinephrinemediated by the beta-3-adrenergic receptors.83 In this regard, an
antimuscarinic agent that has both M2 and M3 antagonist effects
may directly inhibit detrusor contraction and indirectly inhibit the
inhibitory effect of detrusor relaxation, and therefore have a better
therapeutic effect on OAB compared to that having a selective M3
antimuscarinic effect. Clinicians should offer oral antimuscarinics,
including darifenacin, fesoterodine, oxybutynin, solifenacin, tol-
terodine, or trospium as ﬁrst line antimuscarinic therapy. However,
not all patients can beneﬁt from an antimuscarinic agent. Some
patients with OAB and hypersensitive bladder may respond to
antimuscarinic agents.74 Adverse effects such as dizziness, dry
mouth, blurred vision, and constipation might be intolerable for
some elderly patients.84
Treatment for LUTS suggestive of BPH has traditionally involved
the use of alpha-1 adrenoceptor antagonists, 5ARI, and phytother-
apy. This treatment can effectively improve OAB symptoms in most
patients with BOO and OAB. The focus of treatment for LUTS has
thus shifted from the prostate to the bladder and other extrapro-
static sites.85 Selective beta-3 adrenoceptor agonists and anti-
muscarinics are potentially useful agents for treating LUTS,
particularly for storage symptoms secondary to outﬂow obstruc-
tion. Oral antimuscarinics are usually used as second line therapy
for male LUTS-associated OAB, reducing symptoms, but are
commonly associated with non-life-threatening side effects (e.g.,
dry mouth, constipation, dry eyes, blurred vision, dyspepsia, UTI,
urinary retention, impaired cognitive function). There is no
compelling evidence for differential efﬁcacy across medications.
Combination treatment with an alpha-blocker (tamsulosin) plus
an anticholinergic (tolterodine) improves QoL in patients with BOO
and concomitant detrusor instability. Interestingly, no acute uri-
nary retention was observed and tolterodine did not affect the
quality of urine ﬂow or residual urine volume.86 The efﬁcacy of
antimuscarinics has been proven in different trials regarding
different storage symptom end points only in men with low PVR
urine volumes at baseline (< 200 mL). Overall, the addition of an
antimuscarinic to the treatment of a patient with BOO and
concomitant OAB seems to offer an amelioration of the symptoms
and a moderate improvement in QoL.87 However, ﬁrst line anti-
muscarinic monotherapy has been proven safe and effective within
12 weeks in selected patients with BPH. Higher baseline IPSS-S,
higher baseline Qmax, and lower TPV were predictors of success-
ful antimuscarinic monotherapy.88
OAB is an abnormal bladder condition; sensory receptors or
beta-adrenergic receptors might overexpress and cause abnormal
clinical presentation. For patients whose OAB symptoms were
refractory to an antimuscarinic agent, a newly launched beta-3
adrenergic agonist might be therapeutically effective. Solabe-
gron signiﬁcantly reduced the symptoms of OAB in women with
moderate to severe OAB. Solabegron was safe, well tolerated, and
did not demonstrate signiﬁcant differences in adverse events
(AEs) as compared to placebo. Beta-3 adrenoceptor agonists may
represent a new therapeutic approach for treating OAB
symptoms.89
8.2. In patients with OAB refractory to the ﬁrst line treatment,
adding a second antimuscarinic is feasible. (LE 2b, Grade B)
However, the adverse effects should be balanced for long term
treatment. (LE 3b, Grade B)
Clinicians should not use antimuscarinics in patients with nar-
row angle glaucoma unless approved by the treating ophthalmol-
ogist and should use antimuscarinics with extreme caution in
patients with impaired gastric emptying or a history of urinary
retention. If a patient experiences inadequate symptom control
and/or unacceptable adverse drug events with one antimuscarinic
C.-C. Wang et al. / Urological Science 26 (2015) 7e1612medication, then a dose modiﬁcation or a different antimuscarinic
medication may be tried. Clinicians should manage constipation
and drymouth before abandoning effective antimuscarinic therapy.
Management may include bowel management, ﬂuid management,
dose modiﬁcation, or alternative antimuscarinics. Clinicians must
use caution in prescribing antimuscarinics in patients who are us-
ing other medications with anticholinergic properties. Clinicians
should use caution in prescribing antimuscarinics in frail elderly
patients, particularly the elderly; the potential CNS adverse effects
of each anticholinergic agent must be weighed against the severity
of OAB symptoms.90 Nevertheless, in older men with BPH and
storage symptoms treated with alpha-blockers and/or 5ARI, addi-
tive treatment with tolterodine ER in older menwith BPH/BOO and
signiﬁcant storage symptoms has been proven to be a beneﬁcial
and safe therapeutic option.91 Several recent trials also proved that
adding antimuscarinics to an alpha-blocker provided individuals
with improvement of residual OAB symptoms in men with
LUTS.51,92e94
9. Minimally invasive therapies for OAB
9.1. Botulinum toxin A 100 U is recommended in patients with
refractory OAB, excluding patients with BOO. (LE 1a, Grade A)
Ageing patients with medical comorbidity or a PVR > 100 mL
should be carefully informed of the risks of urinary retention or
UTI. (LE 2a, Grade B)
Intravesical injection of onabotulinumtoxinA is effective for
idiopathic DO refractory to antimuscarinics. Several randomized,
placebo-controlled studies have proven that onabotulinumtoxinA
100 U was well tolerated and produced signiﬁcantly and clinically
relevant improvements in all OAB symptoms, patient-reported
beneﬁts, and HRQoL in patients inadequately managed by anti-
cholinergics.95e97 Improvement of urgency severity is signiﬁ-
cantly associated with a higher success rate at 3 months and a
longer therapeutic duration after intravesical botulinum toxin-A
(BoNT-A) injection for idiopathic detressor overactivity (IDO).98
However, safety is a major concern, especially in elderly in-
dividuals. Although safety and efﬁcacy were similar between
elderly patients without frailty and younger patients, an
increased risk of large PVR urine volume and a lower long term
success rate in frail elderly patients were noted after intravesical
onabotulinumtoxinA injection for refractory idiopathic detrusor
overactivity.99
A single onabotulinumtoxinA treatment, with doses  100 U,
resulted in statistically signiﬁcant and clinically meaningful
improvement in HRQoL byWeek 2 comparedwith placebo, and this
improvement was sustained for  36 weeks in patients with idio-
pathic OAB and urgency urinary incontinence who were inade-
quately managed by oral antimuscarinics.97 A total of 207 injections
were performed in 100 patients. BoNT-A can provide a safe and
effective medium term management option for patients with re-
fractory IDO. The most common reasons cited for stopping treat-
ment were poor efﬁcacy and clean intermittent self catheterization
(CISC)-related issues.100 Intravesical injection of BoNT-A provides
effective treatment for DO and OAB. However, the high rates of
treatment-related AEs prevent its more widespread use. Male sex,
baseline PVR  100 mL, comorbidity, and BoNT-A dose > 100 U are
risk factors for an increasing incidence of AEs after intravesical
BoNT-A injection for IDO.101
Intravesical BoNT-A therapy is an effective short term treatment
for OAB.With time, two-thirds of patients (61.3%) had discontinued
intravesical BoNT-A therapy at 36 months, with a 63.8% discon-
tinuation rate at 60 months. The main reasons for discontinuation
were tolerability issues, mainly urinary tract infections and theneed for clean intermittent self-catheterization. Primary and sec-
ondary losses of efﬁcacy were of secondary importance.96
9.2. Percutaneous tibial nerve stimulation and sacral nerve
stimulation may be considered as a clinically signiﬁcant
alternative therapy for OAB. (LE 3b, Grade B)
Electrostimulation is an established therapeutic option for
neurogenic urinary disorders. Chronic transcutaneous posterior
tibial nerve stimulation was also shown to be effective in the
management of severe OAB, without compromising bladder
emptying or inducing side effects. Treatment may be effective even
in the absence of an acute cystometric effect.102 A randomized,
multicenter, controlled study compared the effectiveness of
percutaneous tibial nerve stimulation to extended-release tolter-
odine. The reduction in OAB symptoms along with global response
assessments were evaluated. The study demonstrates that percu-
taneous tibial nerve stimulation is safe with statistically signiﬁcant
improvements in patient assessment of OAB symptoms, and with
objective effectiveness comparable to that of pharmacotherapy.
Percutaneous tibial nerve stimulation may be considered a clini-
cally signiﬁcant alternative therapy for OAB.103 After 12 weeks,
individuals randomized to weekly percutaneous tibial nerve stim-
ulation were offered an additional 9 months of treatment with
assessments at 6 months and 12 months from baseline. The dura-
bility of response demonstrates the effectiveness of percutaneous
tibial nerve stimulation as a viable, long term therapy for OAB.104
Posterior tibial nerve stimulation can beneﬁt a carefully selected
group of patients with moderately severe baseline incontinence
and frequency and willingness to comply with the posterior tibial
nerve stimulation protocol.
Sacral nerve stimulation (SNS) is thought to act via stimulation
of somatic afferents which inhibit the transmission of afferent
messages arising from the bladder.105 Therefore, SNS has been
applied to improve urgency, frequency, and urge incontinence.106 A
retrospective review performed on SNS patients who received an
implantable pulse generator, from December 1993 to December
2004, demonstrated that SNS is an effective method for treating
certain types of voiding dysfunction. Although 53% of patients
experienced at least one RE, 97% of patients were mild to moderate
and did not appear to affect the continued use of this therapy.107
The carryover effect could be caused by negative modulation of
excitatory synapses in the central micturition reﬂex pathway.108
Although the mechanisms of neuromodulation remain unclear,
this therapeutic modality has been used to treat patients with OAB
and who are refractory to conventional therapies. However, pa-
tients should be informed about the frequent and moderately se-
vere AEs, including pain at the stimulator and lead sites, lead
migration, infection/irritation, electric shock, the need for addi-
tional surgeries (a side effect that occurred in > 30% of patients),
and periodic battery replacement.
10. Surgical treatment
10.1. Although most patients with OAB can be successfully
treated with oral medication and intravesical treatments, some
patients might still be refractory to treatment. For those patients
suffering from intractable OAB symptoms, we should search for
the possible uncovered pathologies including residual BOO,
urethral incompetence, and contracted bladder and perform the
appropriate surgery. (LE 3b, Grade B)
OAB associated with male LUTS/BPH can be relieved after sur-
gical prostatectomy. TURP signiﬁcantly reduces the incidence of
detrusor overactivity concurrent with BOO.109 A multivariate
Fig. 1. The algorithm of diagnosis and treatment of male overactive bladder syndrome. BOO ¼ bladder outlet obstruction; Botox ¼ botulinum toxin; DHIC ¼ detrusor hyperactivity
and inadequate contractility; ISD ¼ intrinsic sphincter deﬁciency; OAB ¼ overactive bladder syndrome; PTNS ¼ posterior tibial nerve stimulation; SNS ¼ sacral nerve stimulation;
UUI ¼ urgency urinary incontinence.
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(continued )
Statement LE Grade
11 In patients with OAB refractory to the ﬁrst line treatment, adding a
second antimuscarinic is feasible. However, the adverse effects
should be balanced for long-term treatment.
2b B
12 Botulinum toxin A 100 U is recommended in patients with
refractory OAB, excluding patients with BOO.
1a A
13 For those patients suffering from intractable OAB symptoms, we
should search for the possible uncovered pathologies including
residual BOO, urethral incompetence, and contracted bladder, and
perform appropriate surgery.
3b B
C.-C. Wang et al. / Urological Science 26 (2015) 7e1614analysis suggested that the baseline degree of detrusor contractility
was consistently associated with the improvement in each OAB
symptom and good detrusor contractility is essential for the
symptomatic beneﬁts after the surgical relief of BOO. Aging males
with good urinary ﬂow rates appear to experience a reduced
improvement of nocturia symptoms after undergoing TURP.110
Enterocystoplasty is more helpful in intractable DO than in
interstitial cystitis. Detrusor myomectomy (autoaugmentation) has
yielded excellent results in patients with neurogenic causes of DO.
Urinary diversion is rarely required in DO, but may be preferable to
enterocystoplasty when severe pelvic pain is present. Cystour-
ethrectomy with urinary diversion or bladder augmentation is the
ultimate option for the treatment of refractory DO, particularly in
patients with intractable pain.111
When patients are refractory to nonsurgical therapies and are
found to have a contracted bladder or low bladder compliance,
enterocystoplasty using a segment of terminal ileum or the ileo-
cecal portion is feasible to rebuild a low pressure, large compliant
bladder that may resolve the OAB symptoms within 3 months.112
Lotenfoe et al113 achieved an overall success rate of 73% with cys-
tourethrectomy and colonic urinary diversion. They noted the
success rate was 88% in patients with bladder capacities < 400 mL,
but only 20% in patients with capacities > 400 mL.11. Conclusion
LUTS are commonly divided into storage, voiding, and post-
micturition symptoms, and are highly prevalent in elderly men.
LUTS can result from a complex interplay of pathophysiologic fea-
tures that can include bladder dysfunction and bladder outlet
dysfunction such as BPO or poor relaxation of the urethral
sphincter. Diagnosis of OAB in male LUTS leads to accurate treat-
ment in men with residual storage symptoms after treatment for
LUTS. An algorithm of the diagnosis and treatment of male OAB has
been constructed for clinical reference (Fig. 1).12. Level of evidence and grade of recommendationsStatement LE Grade
1 LUTS are highly prevalent among older men and have a negative
impact on health-related QoL.
1a A
2 Antimuscarinics in combination with alpha-1 receptor
antagonists, or alone, improve OAB symptoms in men with and
without BOO.
1a A
3 Diagnosis of OAB in male patients with LUTS should be based on
symptom of urgency with/without urgency incontinence.
A
4 The initial assessment of OAB in men with LUTS should include
the past history, present illness, physical examination, and
laboratory examination.
A
5 A detailed history taking and neurological examination including
bulbocavernosus reﬂex, deep tendon reﬂex test, and saddle
anesthesia will be helpful in differentiation between idiopathic
and neurogenic OAB.
A
6 DO and urethral sphincter dysfunction should also be considered
in young men with LUTS or a small prostate.
2b B
7 Urodynamic testing is indicated especially when male patients
with LUTS are ready to undergo invasive therapy for LUTS, such as
TURP or laser prostatectomy.
2b B
8 Patients should be encouraged to continue behavioral
modiﬁcation even though they are successfully treated with
medication.
2b B
9 Antimuscarinics or beta-3 adrenoceptor agonists are
recommended for men with LUTS suggestive of OAB and without
evidence of BOO.
1a A
10 Men with both voiding and storage LUTS are recommended to
take an alpha-blocker with/without 5ARI ﬁrst, followed by
antimuscarinics or a beta-3 adrenoceptor agonist.
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